Earnings Data
Report Date
Aug 05, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
7.7Last Year’s EPS
5.52Same Quarter Last Year
Strong Buy
Based on 21 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a strongly positive operational and financial picture: exceptional revenue and earnings growth, raised guidance, robust international momentum for incretins, successful clinical readouts (including cardiovascular safety for Foundayo), an ambitious pipeline with 42 active Phase III programs, and multiple strategic acquisitions to broaden capabilities. The principal concerns are meaningful pricing pressure (expected low-to-mid-teens headwind), increased marketing and R&D spend, access variability (Medicaid and payer coverage), early-stage uncertainty around Foundayo's ultimate contribution, and competitive/generic dynamics in some markets. On balance, the highlights materially outweigh the lowlights.Company Guidance
Strong Top-Line Revenue Growth
Revenue grew 56% year-over-year in Q1 2026 compared to Q1 2025; updated full-year revenue guidance raised by $2 billion at each end to $82 billion–$85 billion (midpoint = ~28% growth vs 2025).
Major Contribution from Key Products (Incretin & Others)
Combined global revenue for Mounjaro and Suven was $12.8 billion in Q1, contributing $6.7 billion of growth vs Q1 2025; key products collectively grew by more than $7 billion year-over-year.
Outstanding Prescriptions and International Momentum
U.S. incretin analog total prescriptions grew >80% in Q1; international incretin market increased 77% YoY (IQVIA gross sales). Mounjaro achieved strong international uptake, with average OUS market share above 53% and market share ~60% in select markets (e.g., Korea).
Record Earnings and Margin Improvement
Non-GAAP EPS was $8.55 in Q1 2026 versus $3.34 in Q1 2025. Non-GAAP performance margin was 50%, an increase of ~7 percentage points year-over-year. Gross margin was 82.6% of revenue (down ~1 percentage point YoY).
Foundayo (oral GLP-1) U.S. Approval and Early Launch Traction
Foundayo (orforgopron) approved by U.S. FDA for obesity and launched in April 2026; early commercial indicators include broad pharmacy availability (April 9), availability on >12 major telehealth platforms, confirmation of commercial access at 2 of 3 largest PBMs (mid-May), >8,000 prescribers (≈1/3 new to class), and >20,000 patients treated to date with 80% of prescriptions new-to-class.
Positive Clinical and Pipeline Milestones
Multiple positive Phase III results: Foundayo ACHIEVE I (cardiovascular safety: 16% lower MACE risk; secondary 23% lower risk; exploratory 57% lower all-cause death not controlled for multiplicity), positive TRANSCEND P2D-1 for retatrutide (A1c lowered 1.7–2.0 percentage points; weight loss 11.1–16.6 kg / 25–37 lbs), positive data in CLL for pertibrutinib, pediatric atopic dermatitis, and combination results (ixekizumab + tirzepatide). Company has 42 active Phase III programs and initiated multiple new Phase III programs across therapeutic areas.
Active Business Development and Portfolio Expansion
Announced/acquired multiple strategic transactions including Orna Therapeutics, Syntessa, Colonia Therapeutics, Ajax Therapeutics, Ventix Biosciences, and Contessa Pharmaceuticals to expand capabilities in in vivo CAR-T, sleep-wake disorders, next-gen JAK inhibitors, NLRP3 inhibitors, and orexin receptor agonists.
Capital Returns and Shareholder Discipline
Distributed $1.5 billion in dividends and executed $2.4 billion in share repurchases in Q1; company increased FY non-GAAP EPS guidance to $35.50–$37 (up $2 at both ends) and reiterated commitment to disciplined BD to create shareholder value.
DE:LLY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:LLY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 30, 2026 | €731.23 | €786.33 | +7.54% |
Feb 04, 2026 | €871.23 | €929.53 | +6.69% |
Oct 30, 2025 | €708.14 | €724.46 | +2.30% |
Aug 07, 2025 | €640.14 | €546.31 | -14.66% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Eli Lilly And Company (DE:LLY) report earnings?
Eli Lilly And Company (DE:LLY) is schdueled to report earning on Aug 05, 2026, Before Open (Confirmed).
What is Eli Lilly And Company (DE:LLY) earnings time?
Eli Lilly And Company (DE:LLY) earnings time is at Aug 05, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Eli Lilly And Company stock?
The P/E ratio of Eli Lilly & Co is N/A.
What is DE:LLY EPS forecast?
DE:LLY EPS forecast for the fiscal quarter 2026 (Q2) is 7.7.
